Which has higher valuation & earnings, ABVX or BIIB?

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Biogen $9.89B 3.35 $1.29B $5.65 39.68

Is ABVX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Biogen 8.32% 11.18% 6.88%

Does the media favor ABVX or BIIB?

In the previous week, Biogen had 39 more articles in the media than Abivax. MarketBeat recorded 40 mentions for Biogen and 1 mentions for Abivax. Biogen's average media sentiment score of 1.22 beat Abivax's score of 1.19 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 29 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABVX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Alnylam Pharmaceuticals' score of 0.90 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or BNTX more profitable?

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% BioNTech -63.54% -6.86% -6.00%

Does the media favor ABVX or BNTX?

In the previous week, BioNTech had 17 more articles in the media than Abivax. MarketBeat recorded 18 mentions for BioNTech and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat BioNTech's score of -0.22 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ABVX or INSM?

Abivax has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Insmed $1.14B 24.22 -$1.28B -$4.11 N/A

Is ABVX or INSM more profitable?

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Insmed -76.94% -123.94% -44.30%

Does the media prefer ABVX or INSM?

In the previous week, Insmed had 9 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Insmed and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Insmed's score of 1.00 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ROIV or ABVX?

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $7.53M 3,279.70 -$299.77M -$0.53 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ROIV or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Abivax N/A -99.02% -70.26%

Does the media prefer ROIV or ABVX?

In the previous week, Roivant Sciences had 21 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Roivant Sciences and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Roivant Sciences' score of 0.74 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abivax (ABVX) Competitors

$114.74 +3.66 (+3.29%)

As of 02:01 PM Eastern

Compare

ABVX vs. BIIB, ALNY, BNTX, INSM, and ROIV

Should you buy Abivax stock or one of its competitors? Abivax's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abivax compare to Biogen?

Abivax (NASDAQ:ABVX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Abivax has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Biogen	$9.89B	3.35	$1.29B	$5.65	39.68

In the previous week, Biogen had 39 more articles in the media than Abivax. MarketBeat recorded 40 mentions for Biogen and 1 mentions for Abivax. Biogen's average media sentiment score of 1.22 beat Abivax's score of 1.19 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	29 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 36.40%. Biogen has a consensus price target of $228.50, indicating a potential upside of 1.92%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

47.9% of Abivax shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Biogen	8.32%	11.18%	6.88%

Summary

Biogen beats Abivax on 13 of the 16 factors compared between the two stocks.

How does Abivax compare to Alnylam Pharmaceuticals?

Abivax (NASDAQ:ABVX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Alnylam Pharmaceuticals' score of 0.90 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Alnylam Pharmaceuticals	$3.71B	9.57	$313.75M	$5.38	49.39

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Abivax's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 36.40%. Alnylam Pharmaceuticals has a consensus target price of $386.14, suggesting a potential upside of 45.33%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Alnylam Pharmaceuticals beats Abivax on 14 of the 16 factors compared between the two stocks.

How does Abivax compare to BioNTech?

Abivax (NASDAQ:ABVX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Abivax has higher earnings, but lower revenue than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
BioNTech	$3.25B	8.05	-$1.29B	-$7.83	N/A

In the previous week, BioNTech had 17 more articles in the media than Abivax. MarketBeat recorded 18 mentions for BioNTech and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat BioNTech's score of -0.22 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral

47.9% of Abivax shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 36.40%. BioNTech has a consensus price target of $127.44, indicating a potential upside of 23.31%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Abivax has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

BioNTech beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Abivax compare to Insmed?

Abivax (NASDAQ:ABVX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 36.40%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 62.90%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Insmed had 9 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Insmed and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Insmed's score of 1.00 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Insmed	-76.94%	-123.94%	-44.30%

Abivax has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Insmed	$1.14B	24.22	-$1.28B	-$4.11	N/A

Summary

Insmed beats Abivax on 9 of the 16 factors compared between the two stocks.

How does Abivax compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,279.70	-$299.77M	-$0.53	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Abivax	N/A	-99.02%	-70.26%

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Roivant Sciences had 21 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Roivant Sciences and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Roivant Sciences' score of 0.74 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Roivant Sciences currently has a consensus target price of $35.14, indicating a potential upside of 2.74%. Abivax has a consensus target price of $156.50, indicating a potential upside of 36.40%. Given Abivax's higher probable upside, analysts clearly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Roivant Sciences beats Abivax on 11 of the 16 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.00B	$4.02B	$7.26B	$12.91B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-22.00	12.64	273.83	25.42
Price / Sales	N/A	1,362.02	676.21	123.96
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	17.46	16.28	12.89	6.17
Net Income	-$380.27M	-$22.72M	$3.48B	$349.24M
7 Day Performance	0.38%	-1.62%	-0.36%	-1.42%
1 Month Performance	-8.05%	10.88%	6.49%	2.53%
1 Year Performance	37.17%	53.32%	25.06%	15.84%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	2.5142 of 5 stars	$114.74 +3.3%	$156.50 +36.4%	+35.5%	$10.00B	N/A	N/A	61	News Coverage Positive News
BIIB Biogen	3.0753 of 5 stars	$217.35 -1.9%	$227.79 +4.8%	+59.5%	$32.11B	$9.89B	38.47	7,500	Trending News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.5946 of 5 stars	$234.50 -0.9%	$386.14 +64.7%	-40.2%	$31.38B	$3.71B	43.59	2,770	Analyst Forecast
BNTX BioNTech	3.1508 of 5 stars	$103.20 -7.4%	$127.81 +23.8%	+3.2%	$26.10B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7117 of 5 stars	$118.29 -2.6%	$205.52 +73.7%	-12.8%	$25.83B	$1.14B	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors